Aenova to take over Euro Vital Pharma
The company develops medicines and health products for private-label brands
The Aenova Group, a leading provider of services for the development, manufacturing and commercialisation of solid dosage forms, is to take over Euro Vital Pharma for an undisclosed sum.
The acquisition is conditional on the approval of the relevant competition authorities and is likely to be completed by the end of the year.
Euro Vital Pharma, based in Hamburg, Germany is a developer and manufacturer of health products for private-label brands.
The company has more than 30 medicines approved for the German market, together with dietary supplements and cosmetic products, which consist primarily of salves, gels, syrups and nasal sprays.
Aenova says the company’s range complements its portfolio of licensed products.
The acquisition enables us to expand our intellectual property and strengthen our position in private-label and branded products
‘The acquisition of Euro Vital Pharma is not just the next logical step in our growth strategy,’ said Heiner Hoppmann, CEO of the Aenova Group. ‘It also enables us to expand our intellectual property and, at the same time, to strengthen our position as the market-leading service provider for private-label customers and brand customers selling products in pharmacies, chemist stores and food retail chains.
‘The semi-solid and liquid dosage forms produced by Euro Vital Pharma are an excellent complement to our portfolio.’
In October Aenova agreed to buy the Temmler Group, a contract pharmaceutical manufacturer based in Marburg, Germany.
Aenova was formed following the merger of Dragenopharm and Swiss Caps and is now owned by private equity firm BC Partners. It has seven production sites in Germany, Switzerland, France, Romania and the US and employs around 1,600 people. The firm’s annual turnover is around €280m. Its portfolio consists of solid dosage forms, such as soft gelatin capsules, hard capsules, conventional tablets, film-coated tablets, dragées and effervescent tablets. The company’s headquarters are in Pähl, near Munich.
Aenova has seven production sites in five countries (Germany, Switzerland, France, Romania and the US) and employs a total of around 1,600 people.